PTGS2 and malignant colon neoplasm: Thus, celecoxib was shown to cause inhibition of ICAM-1 expression in colon cancer cells and a decreased adhesion to fetal calf serum (FCS)-coated plastic wells with both events mediated via a COX-2-independent pathway [44].